Review



rb1 enhancer grna crispr cas9  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Addgene inc rb1 enhancer grna crispr cas9
    FIGURE 1 | <t>RB1</t> expression is low in TNBC. (A) RB1 expression levels in tumour tissues were compared to adjacent tissues using the TCGA datasets. (B) RB1 expression levels in the basal subtype were compared to other subtypes using the TCGA datasets. (C) Kaplan–Meier plot illustrates the overall survival (OS) of TNBC patients with high or low RB1 expression. (D, E) RB1 mRNA and protein expression levels were analysed in both CCLE (D) and TCGA (E) datasets. Black dots signify no mutation in the RB1 gene, while red dots indicate the presence of a mutation in the RB1 gene.
    Rb1 Enhancer Grna Crispr Cas9, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1851 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rb1 enhancer grna crispr cas9/product/Addgene inc
    Average 96 stars, based on 1851 article reviews
    rb1 enhancer grna crispr cas9 - by Bioz Stars, 2026-02
    96/100 stars

    Images

    1) Product Images from "Increasing RB1 Expression by Targeting EZH2 in Triple-Negative Breast Cancer."

    Article Title: Increasing RB1 Expression by Targeting EZH2 in Triple-Negative Breast Cancer.

    Journal: Journal of cellular and molecular medicine

    doi: 10.1111/jcmm.70384

    FIGURE 1 | RB1 expression is low in TNBC. (A) RB1 expression levels in tumour tissues were compared to adjacent tissues using the TCGA datasets. (B) RB1 expression levels in the basal subtype were compared to other subtypes using the TCGA datasets. (C) Kaplan–Meier plot illustrates the overall survival (OS) of TNBC patients with high or low RB1 expression. (D, E) RB1 mRNA and protein expression levels were analysed in both CCLE (D) and TCGA (E) datasets. Black dots signify no mutation in the RB1 gene, while red dots indicate the presence of a mutation in the RB1 gene.
    Figure Legend Snippet: FIGURE 1 | RB1 expression is low in TNBC. (A) RB1 expression levels in tumour tissues were compared to adjacent tissues using the TCGA datasets. (B) RB1 expression levels in the basal subtype were compared to other subtypes using the TCGA datasets. (C) Kaplan–Meier plot illustrates the overall survival (OS) of TNBC patients with high or low RB1 expression. (D, E) RB1 mRNA and protein expression levels were analysed in both CCLE (D) and TCGA (E) datasets. Black dots signify no mutation in the RB1 gene, while red dots indicate the presence of a mutation in the RB1 gene.

    Techniques Used: Expressing, Mutagenesis

    FIGURE 2 | The negative correlation between EZH2 and RB1 in TNBC. (A) The Venn diagram illustrates 17 epigenetic regulatory proteins identi- fied from the comparison of 12,301 genes negatively correlated with RB1 versus 167 epigenetic regulatory enzymes (above). The correlation diagram demonstrates that these 17 epigenetic regulatory enzymes exhibit a negative correlation with RB1 (below). (B) Transcriptional analysis from the TCGA database reveals a negative correlation between EZH2 and RB1. Each dot represents a TNBC patient. (C) Western blot analysis of EZH2 and RB1 expression in 15 TNBC cell lines. (D) Quantitative assessment of the results from (C) conducted using ImageJ.
    Figure Legend Snippet: FIGURE 2 | The negative correlation between EZH2 and RB1 in TNBC. (A) The Venn diagram illustrates 17 epigenetic regulatory proteins identi- fied from the comparison of 12,301 genes negatively correlated with RB1 versus 167 epigenetic regulatory enzymes (above). The correlation diagram demonstrates that these 17 epigenetic regulatory enzymes exhibit a negative correlation with RB1 (below). (B) Transcriptional analysis from the TCGA database reveals a negative correlation between EZH2 and RB1. Each dot represents a TNBC patient. (C) Western blot analysis of EZH2 and RB1 expression in 15 TNBC cell lines. (D) Quantitative assessment of the results from (C) conducted using ImageJ.

    Techniques Used: Comparison, Western Blot, Expressing

    FIGURE 3 | Inhibiting EZH2 improves RB1 expression. (A, B) Western blot analysis of EZH2, RB1 and H3K27me3 levels in MDA-MB-468 cells following shEZH2 treatment (A) and in HCC1806 cells after CRISPR-KO of EZH2 (B). GAPDH and H3 were utilised as loading controls. (C–F) Western blot analysis of RB1 and H3K27me3 levels in MDA-MB-468 (C), MDA-MB-436 (D), MDA-MB-231 (E) and HCC1806 (F) cells post-treatment with UNC1999 or EPZ6438. GAPDH and H3 served as loading controls. Quantitative analysis of the results was performed using ImageJ. (G–J) The relative mRNA levels of RB1 to GAPDH were determined in (G) MDA-MB-468, (H) MDA-MB-436, (I) MDA-MB-231 and (J) HCC1806 cells post- treatment with UNC1999 or EPZ6438.
    Figure Legend Snippet: FIGURE 3 | Inhibiting EZH2 improves RB1 expression. (A, B) Western blot analysis of EZH2, RB1 and H3K27me3 levels in MDA-MB-468 cells following shEZH2 treatment (A) and in HCC1806 cells after CRISPR-KO of EZH2 (B). GAPDH and H3 were utilised as loading controls. (C–F) Western blot analysis of RB1 and H3K27me3 levels in MDA-MB-468 (C), MDA-MB-436 (D), MDA-MB-231 (E) and HCC1806 (F) cells post-treatment with UNC1999 or EPZ6438. GAPDH and H3 served as loading controls. Quantitative analysis of the results was performed using ImageJ. (G–J) The relative mRNA levels of RB1 to GAPDH were determined in (G) MDA-MB-468, (H) MDA-MB-436, (I) MDA-MB-231 and (J) HCC1806 cells post- treatment with UNC1999 or EPZ6438.

    Techniques Used: Expressing, Western Blot, CRISPR

    FIGURE 4 | Inhibiting EZH2 elevates H3K27ac enrichment at the RB1 enhancer region. (A) ATAC-seq tracks the RB1 gene locus in 15 TNBC cell lines, displaying chromatin openness using IgV visualisation software. The cell lines are arranged from top to bottom in descending order of RB1 ex- pression levels, as shown in Figure 2C. (B, C) ChIP-qPCR analysis of H3K27ac at the RB1 enhancer region in MDA-MB-436 (B) or MDA-MB-231 (C) after EPZ6438 treatment. (D) Western blot analysis of RB1 levels in HCC1806 cells with CRISPR knock-out of the RB1 enhancer region. (E) Relative mRNA levels of RB1 to GAPDH in HCC1806 cells with CRISPR knock-out of the RB1 enhancer region.
    Figure Legend Snippet: FIGURE 4 | Inhibiting EZH2 elevates H3K27ac enrichment at the RB1 enhancer region. (A) ATAC-seq tracks the RB1 gene locus in 15 TNBC cell lines, displaying chromatin openness using IgV visualisation software. The cell lines are arranged from top to bottom in descending order of RB1 ex- pression levels, as shown in Figure 2C. (B, C) ChIP-qPCR analysis of H3K27ac at the RB1 enhancer region in MDA-MB-436 (B) or MDA-MB-231 (C) after EPZ6438 treatment. (D) Western blot analysis of RB1 levels in HCC1806 cells with CRISPR knock-out of the RB1 enhancer region. (E) Relative mRNA levels of RB1 to GAPDH in HCC1806 cells with CRISPR knock-out of the RB1 enhancer region.

    Techniques Used: Software, ChIP-qPCR, Western Blot, CRISPR, Knock-Out



    Similar Products

    rb1 enhancer grna crispr cas9  (Addgene inc)
    96
    Addgene inc rb1 enhancer grna crispr cas9
    FIGURE 1 | <t>RB1</t> expression is low in TNBC. (A) RB1 expression levels in tumour tissues were compared to adjacent tissues using the TCGA datasets. (B) RB1 expression levels in the basal subtype were compared to other subtypes using the TCGA datasets. (C) Kaplan–Meier plot illustrates the overall survival (OS) of TNBC patients with high or low RB1 expression. (D, E) RB1 mRNA and protein expression levels were analysed in both CCLE (D) and TCGA (E) datasets. Black dots signify no mutation in the RB1 gene, while red dots indicate the presence of a mutation in the RB1 gene.
    Rb1 Enhancer Grna Crispr Cas9, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rb1 enhancer grna crispr cas9/product/Addgene inc
    Average 96 stars, based on 1 article reviews
    rb1 enhancer grna crispr cas9 - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    crispr cas9 based knockout line creation single guide rna sequences  (Addgene inc)
    96
    Addgene inc crispr cas9 based knockout line creation single guide rna sequences
    FIGURE 1 | <t>RB1</t> expression is low in TNBC. (A) RB1 expression levels in tumour tissues were compared to adjacent tissues using the TCGA datasets. (B) RB1 expression levels in the basal subtype were compared to other subtypes using the TCGA datasets. (C) Kaplan–Meier plot illustrates the overall survival (OS) of TNBC patients with high or low RB1 expression. (D, E) RB1 mRNA and protein expression levels were analysed in both CCLE (D) and TCGA (E) datasets. Black dots signify no mutation in the RB1 gene, while red dots indicate the presence of a mutation in the RB1 gene.
    Crispr Cas9 Based Knockout Line Creation Single Guide Rna Sequences, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/crispr cas9 based knockout line creation single guide rna sequences/product/Addgene inc
    Average 96 stars, based on 1 article reviews
    crispr cas9 based knockout line creation single guide rna sequences - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    grna egfp reporter  (Addgene inc)
    92
    Addgene inc grna egfp reporter
    FIGURE 1 | <t>RB1</t> expression is low in TNBC. (A) RB1 expression levels in tumour tissues were compared to adjacent tissues using the TCGA datasets. (B) RB1 expression levels in the basal subtype were compared to other subtypes using the TCGA datasets. (C) Kaplan–Meier plot illustrates the overall survival (OS) of TNBC patients with high or low RB1 expression. (D, E) RB1 mRNA and protein expression levels were analysed in both CCLE (D) and TCGA (E) datasets. Black dots signify no mutation in the RB1 gene, while red dots indicate the presence of a mutation in the RB1 gene.
    Grna Egfp Reporter, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/grna egfp reporter/product/Addgene inc
    Average 92 stars, based on 1 article reviews
    grna egfp reporter - by Bioz Stars, 2026-02
    92/100 stars
    		  Buy from Supplier
    crispr cas9 gene editing guide rna grna  (Addgene inc)
    96
    Addgene inc crispr cas9 gene editing guide rna grna
    FIGURE 1 | <t>RB1</t> expression is low in TNBC. (A) RB1 expression levels in tumour tissues were compared to adjacent tissues using the TCGA datasets. (B) RB1 expression levels in the basal subtype were compared to other subtypes using the TCGA datasets. (C) Kaplan–Meier plot illustrates the overall survival (OS) of TNBC patients with high or low RB1 expression. (D, E) RB1 mRNA and protein expression levels were analysed in both CCLE (D) and TCGA (E) datasets. Black dots signify no mutation in the RB1 gene, while red dots indicate the presence of a mutation in the RB1 gene.
    Crispr Cas9 Gene Editing Guide Rna Grna, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/crispr cas9 gene editing guide rna grna/product/Addgene inc
    Average 96 stars, based on 1 article reviews
    crispr cas9 gene editing guide rna grna - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    crispr cas9 grna targeting  (Addgene inc)
    96
    Addgene inc crispr cas9 grna targeting
    FIGURE 1 | <t>RB1</t> expression is low in TNBC. (A) RB1 expression levels in tumour tissues were compared to adjacent tissues using the TCGA datasets. (B) RB1 expression levels in the basal subtype were compared to other subtypes using the TCGA datasets. (C) Kaplan–Meier plot illustrates the overall survival (OS) of TNBC patients with high or low RB1 expression. (D, E) RB1 mRNA and protein expression levels were analysed in both CCLE (D) and TCGA (E) datasets. Black dots signify no mutation in the RB1 gene, while red dots indicate the presence of a mutation in the RB1 gene.
    Crispr Cas9 Grna Targeting, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/crispr cas9 grna targeting/product/Addgene inc
    Average 96 stars, based on 1 article reviews
    crispr cas9 grna targeting - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    crispra plasmids containing the guide rna (grna), a dcas9-vp64 and a tgfp reporter gene  (OriGene)
    90
    OriGene crispra plasmids containing the guide rna (grna), a dcas9-vp64 and a tgfp reporter gene
    FIGURE 1 | <t>RB1</t> expression is low in TNBC. (A) RB1 expression levels in tumour tissues were compared to adjacent tissues using the TCGA datasets. (B) RB1 expression levels in the basal subtype were compared to other subtypes using the TCGA datasets. (C) Kaplan–Meier plot illustrates the overall survival (OS) of TNBC patients with high or low RB1 expression. (D, E) RB1 mRNA and protein expression levels were analysed in both CCLE (D) and TCGA (E) datasets. Black dots signify no mutation in the RB1 gene, while red dots indicate the presence of a mutation in the RB1 gene.
    Crispra Plasmids Containing The Guide Rna (Grna), A Dcas9 Vp64 And A Tgfp Reporter Gene, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/crispra plasmids containing the guide rna (grna), a dcas9-vp64 and a tgfp reporter gene/product/OriGene
    Average 90 stars, based on 1 article reviews
    crispra plasmids containing the guide rna (grna), a dcas9-vp64 and a tgfp reporter gene - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    plasmids containing the guide rna (grna), a dcas9-vp64 and a tgfp reporter gene  (OriGene)
    90
    OriGene plasmids containing the guide rna (grna), a dcas9-vp64 and a tgfp reporter gene
    FIGURE 1 | <t>RB1</t> expression is low in TNBC. (A) RB1 expression levels in tumour tissues were compared to adjacent tissues using the TCGA datasets. (B) RB1 expression levels in the basal subtype were compared to other subtypes using the TCGA datasets. (C) Kaplan–Meier plot illustrates the overall survival (OS) of TNBC patients with high or low RB1 expression. (D, E) RB1 mRNA and protein expression levels were analysed in both CCLE (D) and TCGA (E) datasets. Black dots signify no mutation in the RB1 gene, while red dots indicate the presence of a mutation in the RB1 gene.
    Plasmids Containing The Guide Rna (Grna), A Dcas9 Vp64 And A Tgfp Reporter Gene, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plasmids containing the guide rna (grna), a dcas9-vp64 and a tgfp reporter gene/product/OriGene
    Average 90 stars, based on 1 article reviews
    plasmids containing the guide rna (grna), a dcas9-vp64 and a tgfp reporter gene - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    grnas for mef2d reporter experiments  (Addgene inc)
    90
    Addgene inc grnas for mef2d reporter experiments
    FIGURE 1 | <t>RB1</t> expression is low in TNBC. (A) RB1 expression levels in tumour tissues were compared to adjacent tissues using the TCGA datasets. (B) RB1 expression levels in the basal subtype were compared to other subtypes using the TCGA datasets. (C) Kaplan–Meier plot illustrates the overall survival (OS) of TNBC patients with high or low RB1 expression. (D, E) RB1 mRNA and protein expression levels were analysed in both CCLE (D) and TCGA (E) datasets. Black dots signify no mutation in the RB1 gene, while red dots indicate the presence of a mutation in the RB1 gene.
    Grnas For Mef2d Reporter Experiments, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/grnas for mef2d reporter experiments/product/Addgene inc
    Average 90 stars, based on 1 article reviews
    grnas for mef2d reporter experiments - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    hu6 promoter  (Addgene inc)
    93
    Addgene inc hu6 promoter
    FIGURE 1 | <t>RB1</t> expression is low in TNBC. (A) RB1 expression levels in tumour tissues were compared to adjacent tissues using the TCGA datasets. (B) RB1 expression levels in the basal subtype were compared to other subtypes using the TCGA datasets. (C) Kaplan–Meier plot illustrates the overall survival (OS) of TNBC patients with high or low RB1 expression. (D, E) RB1 mRNA and protein expression levels were analysed in both CCLE (D) and TCGA (E) datasets. Black dots signify no mutation in the RB1 gene, while red dots indicate the presence of a mutation in the RB1 gene.
    Hu6 Promoter, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hu6 promoter/product/Addgene inc
    Average 93 stars, based on 1 article reviews
    hu6 promoter - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    FIGURE 1 | RB1 expression is low in TNBC. (A) RB1 expression levels in tumour tissues were compared to adjacent tissues using the TCGA datasets. (B) RB1 expression levels in the basal subtype were compared to other subtypes using the TCGA datasets. (C) Kaplan–Meier plot illustrates the overall survival (OS) of TNBC patients with high or low RB1 expression. (D, E) RB1 mRNA and protein expression levels were analysed in both CCLE (D) and TCGA (E) datasets. Black dots signify no mutation in the RB1 gene, while red dots indicate the presence of a mutation in the RB1 gene.

    Journal: Journal of cellular and molecular medicine

    Article Title: Increasing RB1 Expression by Targeting EZH2 in Triple-Negative Breast Cancer.

    doi: 10.1111/jcmm.70384

    Figure Lengend Snippet: FIGURE 1 | RB1 expression is low in TNBC. (A) RB1 expression levels in tumour tissues were compared to adjacent tissues using the TCGA datasets. (B) RB1 expression levels in the basal subtype were compared to other subtypes using the TCGA datasets. (C) Kaplan–Meier plot illustrates the overall survival (OS) of TNBC patients with high or low RB1 expression. (D, E) RB1 mRNA and protein expression levels were analysed in both CCLE (D) and TCGA (E) datasets. Black dots signify no mutation in the RB1 gene, while red dots indicate the presence of a mutation in the RB1 gene.

    Article Snippet: RB1 enhancer knock- out vectors, containing either a non- targeting control or RB1 enhancer gRNA/CRISPR/Cas9, were constructed using the pLentiCRISPRv2- mCherry vector (Addgene #99154).

    Techniques: Expressing, Mutagenesis

    FIGURE 2 | The negative correlation between EZH2 and RB1 in TNBC. (A) The Venn diagram illustrates 17 epigenetic regulatory proteins identi- fied from the comparison of 12,301 genes negatively correlated with RB1 versus 167 epigenetic regulatory enzymes (above). The correlation diagram demonstrates that these 17 epigenetic regulatory enzymes exhibit a negative correlation with RB1 (below). (B) Transcriptional analysis from the TCGA database reveals a negative correlation between EZH2 and RB1. Each dot represents a TNBC patient. (C) Western blot analysis of EZH2 and RB1 expression in 15 TNBC cell lines. (D) Quantitative assessment of the results from (C) conducted using ImageJ.

    Journal: Journal of cellular and molecular medicine

    Article Title: Increasing RB1 Expression by Targeting EZH2 in Triple-Negative Breast Cancer.

    doi: 10.1111/jcmm.70384

    Figure Lengend Snippet: FIGURE 2 | The negative correlation between EZH2 and RB1 in TNBC. (A) The Venn diagram illustrates 17 epigenetic regulatory proteins identi- fied from the comparison of 12,301 genes negatively correlated with RB1 versus 167 epigenetic regulatory enzymes (above). The correlation diagram demonstrates that these 17 epigenetic regulatory enzymes exhibit a negative correlation with RB1 (below). (B) Transcriptional analysis from the TCGA database reveals a negative correlation between EZH2 and RB1. Each dot represents a TNBC patient. (C) Western blot analysis of EZH2 and RB1 expression in 15 TNBC cell lines. (D) Quantitative assessment of the results from (C) conducted using ImageJ.

    Article Snippet: RB1 enhancer knock- out vectors, containing either a non- targeting control or RB1 enhancer gRNA/CRISPR/Cas9, were constructed using the pLentiCRISPRv2- mCherry vector (Addgene #99154).

    Techniques: Comparison, Western Blot, Expressing

    FIGURE 3 | Inhibiting EZH2 improves RB1 expression. (A, B) Western blot analysis of EZH2, RB1 and H3K27me3 levels in MDA-MB-468 cells following shEZH2 treatment (A) and in HCC1806 cells after CRISPR-KO of EZH2 (B). GAPDH and H3 were utilised as loading controls. (C–F) Western blot analysis of RB1 and H3K27me3 levels in MDA-MB-468 (C), MDA-MB-436 (D), MDA-MB-231 (E) and HCC1806 (F) cells post-treatment with UNC1999 or EPZ6438. GAPDH and H3 served as loading controls. Quantitative analysis of the results was performed using ImageJ. (G–J) The relative mRNA levels of RB1 to GAPDH were determined in (G) MDA-MB-468, (H) MDA-MB-436, (I) MDA-MB-231 and (J) HCC1806 cells post- treatment with UNC1999 or EPZ6438.

    Journal: Journal of cellular and molecular medicine

    Article Title: Increasing RB1 Expression by Targeting EZH2 in Triple-Negative Breast Cancer.

    doi: 10.1111/jcmm.70384

    Figure Lengend Snippet: FIGURE 3 | Inhibiting EZH2 improves RB1 expression. (A, B) Western blot analysis of EZH2, RB1 and H3K27me3 levels in MDA-MB-468 cells following shEZH2 treatment (A) and in HCC1806 cells after CRISPR-KO of EZH2 (B). GAPDH and H3 were utilised as loading controls. (C–F) Western blot analysis of RB1 and H3K27me3 levels in MDA-MB-468 (C), MDA-MB-436 (D), MDA-MB-231 (E) and HCC1806 (F) cells post-treatment with UNC1999 or EPZ6438. GAPDH and H3 served as loading controls. Quantitative analysis of the results was performed using ImageJ. (G–J) The relative mRNA levels of RB1 to GAPDH were determined in (G) MDA-MB-468, (H) MDA-MB-436, (I) MDA-MB-231 and (J) HCC1806 cells post- treatment with UNC1999 or EPZ6438.

    Article Snippet: RB1 enhancer knock- out vectors, containing either a non- targeting control or RB1 enhancer gRNA/CRISPR/Cas9, were constructed using the pLentiCRISPRv2- mCherry vector (Addgene #99154).

    Techniques: Expressing, Western Blot, CRISPR

    FIGURE 4 | Inhibiting EZH2 elevates H3K27ac enrichment at the RB1 enhancer region. (A) ATAC-seq tracks the RB1 gene locus in 15 TNBC cell lines, displaying chromatin openness using IgV visualisation software. The cell lines are arranged from top to bottom in descending order of RB1 ex- pression levels, as shown in Figure 2C. (B, C) ChIP-qPCR analysis of H3K27ac at the RB1 enhancer region in MDA-MB-436 (B) or MDA-MB-231 (C) after EPZ6438 treatment. (D) Western blot analysis of RB1 levels in HCC1806 cells with CRISPR knock-out of the RB1 enhancer region. (E) Relative mRNA levels of RB1 to GAPDH in HCC1806 cells with CRISPR knock-out of the RB1 enhancer region.

    Journal: Journal of cellular and molecular medicine

    Article Title: Increasing RB1 Expression by Targeting EZH2 in Triple-Negative Breast Cancer.

    doi: 10.1111/jcmm.70384

    Figure Lengend Snippet: FIGURE 4 | Inhibiting EZH2 elevates H3K27ac enrichment at the RB1 enhancer region. (A) ATAC-seq tracks the RB1 gene locus in 15 TNBC cell lines, displaying chromatin openness using IgV visualisation software. The cell lines are arranged from top to bottom in descending order of RB1 ex- pression levels, as shown in Figure 2C. (B, C) ChIP-qPCR analysis of H3K27ac at the RB1 enhancer region in MDA-MB-436 (B) or MDA-MB-231 (C) after EPZ6438 treatment. (D) Western blot analysis of RB1 levels in HCC1806 cells with CRISPR knock-out of the RB1 enhancer region. (E) Relative mRNA levels of RB1 to GAPDH in HCC1806 cells with CRISPR knock-out of the RB1 enhancer region.

    Article Snippet: RB1 enhancer knock- out vectors, containing either a non- targeting control or RB1 enhancer gRNA/CRISPR/Cas9, were constructed using the pLentiCRISPRv2- mCherry vector (Addgene #99154).

    Techniques: Software, ChIP-qPCR, Western Blot, CRISPR, Knock-Out